Proactive Investors - Run By Investors For Investors

The Hydroponics Company acquires world-class biomanufacturing facility, shares up

Notably, receipts from customers for the March quarter were up 31% to $1.079 million.
sign saying acquisition
Total consideration paid for the land and facility is $2.55 million

The Hydroponics Company Ltd (ASX:THC) has acquired biomanufacturing facilities in Queensland for medicinal cannabis.

The acquisition pushes THC to the forefront of the Australian medicinal cannabis industry.

It prompted an 18% increase in shares to 72 cents in early trading.

The facility is one of the largest pharmaceutical botanicals extraction and refinement plants in the Southern Hemisphere.

Large-scale facility means THC can become a global player

The acquisition will enable THC to become a globally significant manufacturer of medicinal cannabis products for Australian and export markets.

The facility provides large-scale capacity required to supply the Australian medicinal cannabis industry.

THC’s chairman Steven Xu said: “This is a game-changing investment undertaken by THC providing it with large-scale, state-of-the-art biomanufacturing capabilities required to lead Australia’s medicinal cannabis industry.

“The addition of this acquisition is a major component of our roll-out strategy that will generate substantial growth for the company.”

READ: The Hydroponics Company boosts executive team to expand medicinal cannabis strategy

THC acquired the facility from international pharmaceutical company LEO Pharma, who are changing their global production plans.

Total consideration paid for the land and facility is $2.55 million.

The facility is a fully functioning biomanufacturing plant with extraction technology to produce a broad range of high quality, pure cannabinoids as Active Pharmaceutical Ingredients (API).

Importantly, THC has also secured the engagement of key personnel with expertise operating the Queensland biomanufacturing operation.

THC moving in line with legislation changes

In January 2018, Federal Government Health Minister Greg Hunt stated that the Turnbull Government would permit the export of Australian manufactured medicinal cannabis products.

When the changes were announced, Hunt said: “This decision will help both the domestic supply and Australian producers by strengthening the opportunities for domestic manufacturers.”

March quarter cash receipts surpass $1 million

Notably, the company's receipts from customers for the March quarter were $1.079 million.

This represents a 31.4% increase on the December quarter, which recorded receipts from customers of $821,000.

THC’s growth can be further exemplified by the fact that its receipts from customers for the entire 2017 calendar year totalled $1.6 million.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full THC profile View Profile

THC Global Group Ltd Timeline

Related Articles

cannabis plant
December 15 2018
The Vancouver-based cannabis group services medical and recreational cannabis markets in Canada and internationally
High Hampton Holdings set to add near term revenue to bottom line with Mojave Jane acquisition
November 13 2018
Mojave Jane is a California-licensed manufacturer of premium cannabis extracts and concentrates for buyers in the US state
cannabis leaf and green tablets
October 30 2018
The company will now proceed with stage II of the human clinical trial.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use